$BTCY

BIOTRICITY INC.

CIK:0001630113|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
REVENUE	$ 4,276,956	$ 3,873,993
Cost of Revenue	746,136	757,193
GROSS PROFIT	3,530,820	3,116,800
EXPENSES
Selling, general and administrative expenses	2,699,308	2,138,692
Research and development expenses	673,444	696,163
TOTAL OPERATING EXPENSES	3,372,752	2,834,855
INCOME (LOSS) FROM OPERATIONS	158,068	281,945
Other income/(expense) [Note 3]	40,904	66,671
Interest expense	(851,753)	(850,254)
Gain/(Loss) upon convertible promissory notes conversion and redemption [Note 8]		8,433
Accretion and amortization expenses	(196,636)	(153,572)
Change in fair value of derivative liabilities [Note 8]	(110,051)	(25,200)
NET LOSS BEFORE INCOME TAXES	(959,468)	(671,977)
Income taxes
NET LOSS BEFORE DIVIDENDS	(959,468)	(671,977)
Preferred Stock Dividends	(110,842)	(82,316)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(1,070,310)	(754,293)
Translation adjustment	422	(36,169)
COMPREHENSIVE LOSS	$ (1,069,888)	$ (790,462)
LOSS PER SHARE, BASIC	$ (0.046)	$ (0.029)
LOSS PER SHARE, DILUTED	$ (0.046)	$ (0.029)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	23,096,373	26,284,734
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	23,096,373	26,284,734

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Mar. 31, 2026
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (959,468)	$ (671,977)
Adjustments to reconcile net loss to net cash used in operations
Stock based compensation	339,970	5,935
Accretion and amortization expenses	196,636	153,572
Change in fair value of derivative liabilities	110,051	25,200
Loss (Gain) on debt and share conversion and redemption		(8,433)
Property, plant and equipment depreciation	1,488	1,488
Changes in operating assets and liabilities:
Operating right of use assets amortization	126,302	110,870	$ 465,839
Accounts receivable, net	572,932	(205,418)
Inventory	(83,707)	(228,041)
Deposits and other receivables	122,675	(49,117)
Advance from Customers
Accounts payable and accrued liabilities	80,348	492,532
Net cash generated (used) in operating activities	507,227	(373,389)
CASH FLOWS FROM INVESTING ACTIVITIES
Property, plant and equipment
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common shares, net
Issuance of preferred shares, net
Conversion of preferred shares
Redemption of preferred shares
Conversion of convertible notes
Exercise of warrants for cash
Issuance of warrants to brokers
Issuance of warrants for private placement holders
Issuance of warrants for services
Federally guaranteed loans
Proceeds from (repayment to) convertible debentures, net
Proceeds from (repayment to) short term loan and promissory notes, net	(184,935)	441,623
Issuance of shares from uplisting
Due to shareholders
Term Loan, net
Preferred Stock Dividend	(6,000)	(5,918)
Net cash provided (used) in financing activities	(190,935)	435,705
Effect of foreign currency translation	422	(36,169)
Net increase (decrease) in cash during the period	316,292	62,316
Cash, beginning of period	149,789	365,145	365,145
Cash, end of period	466,503	391,292	$ 149,789
Supplemental disclosure of cash flow information:
Cash paid for interest	760,948	724,661
Cash paid for taxes

Condensed Consolidated Interim Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2026	Mar. 31, 2026
CURRENT ASSETS
Cash	$ 466,503	$ 149,789
Accounts receivable, net	2,397,736	2,932,899
Inventory [Note 3]	1,425,002	1,341,295
Deposits and other receivables	1,306,801	1,432,501
Total current assets	5,596,042	5,856,484
Deposits and other receivables	112,322	109,297
Long-term accounts receivable	93,077	130,847
Property and equipment [Note 12]	2,157	3,646
Operating right of use assets [Note 10]	219,912	346,214
TOTAL ASSETS	6,023,510	6,446,488
CURRENT LIABILITIES
Accounts payable and accrued liabilities [Note 4]	9,301,716	8,970,870
Convertible promissory notes and short term loans [Note 5]	10,971,841	11,114,209
Term loan, current [Note 6]	14,834,983	14,680,914
Derivative liabilities [Note 8]	450,328	445,893
Advance from customers	1,531,530	1,531,530
Operating lease obligations, current [Note 10]	252,172	397,830
Total current liabilities	37,342,570	37,141,246
Federally guaranteed loans [Note 7]	870,800	870,800
Derivative liabilities [Note 8]	1,502,524	1,396,908
TOTAL LIABILITIES	39,715,894	39,408,954
Mezzanine Equity
Series B Convertible Redeemable preferred stock, $0.001 and $0.001 par value, 600 and 600 shares authorized as of June 30, 2026 and March 31, 2026, respectively, 335 and 335 shares issued and outstanding as of June 30, 2026 and March 31, 2026, respectively [Note 9]	1,714,476	1,714,476
STOCKHOLDERS’ (DEFICIENCY)
Common stock, $0.001 and $0.001 par value, 125,000,000 and 125,000,000 shares authorized as at June 30, 2026 and March 31, 2026, respectively. Issued and outstanding common shares: 20,074,675 and 28,597,315 as at June 30, 2026 and March 31, 2026, respectively, and exchangeable shares of 160,672 and 160,672 outstanding as at June 30, 2026 and March 31, 2026, respectively [Note 9]	20,237	28,759
Shares to be issued 581,599 and 1,005,815 shares of common stock as at June 30, 2026 and March 31, 2026, respectively [Note 9]	279,428	284,668
Additional paid-in-capital	105,542,543	107,621,813
Accumulated other comprehensive loss	(41,518)	(41,940)
Accumulated deficit	(143,640,553)	(142,570,243)
Total stockholders’ (deficiency)	(35,406,860)	(34,676,942)
TOTAL LIABILITIES, MEZZANINE AND STOCKHOLDERS’ DEFICIENCY	6,023,510	6,446,488
Preferred Stocks [Member]
STOCKHOLDERS’ (DEFICIENCY)
Preferred Stock, value	1	1
Series A Preferred Stock [Member]
STOCKHOLDERS’ (DEFICIENCY)
Preferred Stock, value
Series C Preferred Stock [Member]
STOCKHOLDERS’ (DEFICIENCY)
Preferred Stock, value	$ 2,433,002